Verona Pharma Past Earnings Performance
Past criteria checks 0/6
Verona Pharma's earnings have been declining at an average annual rate of -13.9%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 27.9% per year.
Key information
-13.9%
Earnings growth rate
24.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 27.9% |
Return on equity | -21.8% |
Net Margin | n/a |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?
Apr 26Verona Pharma: A Few Points From The Bull And Bear Case
Feb 15Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Jan 26Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Jan 19Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?
Oct 12Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?
Jun 27Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?
Mar 10Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?
Dec 02Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Sep 13Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Aug 19Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Aug 09Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
Feb 04Verona Pharma's ensifentrine successful in mid-stage lung disease study; shares up 8%
Feb 02Enrollment completed in Verona Pharma's study of pMDI ensifentrine in COVID-19
Jan 14Verona Pharma EPS beats by $0.15
Oct 29Revenue & Expenses BreakdownBeta
How Verona Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -54 | 50 | 16 |
30 Sep 23 | 0 | -51 | 44 | 19 |
30 Jun 23 | 0 | -52 | 36 | 24 |
31 Mar 23 | 0 | -61 | 29 | 34 |
31 Dec 22 | 0 | -69 | 25 | 40 |
30 Sep 22 | 0 | -82 | 24 | 51 |
30 Jun 22 | 40 | -55 | 30 | 61 |
31 Mar 22 | 40 | -59 | 32 | 69 |
31 Dec 21 | 40 | -56 | 34 | 64 |
30 Sep 21 | 40 | -57 | 40 | 60 |
30 Jun 21 | 0 | -87 | 37 | 53 |
31 Mar 21 | 0 | -74 | 32 | 42 |
31 Dec 20 | 0 | -65 | 30 | 36 |
30 Sep 20 | 0 | -50 | 21 | 20 |
30 Jun 20 | 0 | -43 | 15 | 25 |
31 Mar 20 | 0 | -46 | 15 | 32 |
31 Dec 19 | 0 | -41 | 10 | 33 |
30 Sep 19 | 0 | -35 | 10 | 42 |
30 Jun 19 | 0 | -25 | 9 | 34 |
31 Mar 19 | 0 | -13 | 9 | 27 |
31 Dec 18 | 0 | -25 | 8 | 25 |
30 Sep 18 | 0 | -30 | 7 | 30 |
30 Jun 18 | 0 | -40 | 8 | 32 |
31 Mar 18 | 0 | -47 | 9 | 35 |
31 Dec 17 | 0 | -28 | 8 | 32 |
30 Sep 17 | 0 | -20 | 8 | 21 |
30 Jun 17 | 0 | -11 | 6 | 15 |
31 Mar 17 | 0 | -8 | 4 | 9 |
31 Dec 16 | 0 | -6 | 3 | 6 |
30 Sep 16 | 0 | -8 | 2 | 6 |
30 Jun 16 | 0 | -7 | 2 | 7 |
31 Mar 16 | 0 | -9 | 2 | 9 |
31 Dec 15 | 0 | -11 | 3 | 11 |
30 Sep 15 | 0 | -10 | 3 | 9 |
30 Jun 15 | 0 | -8 | 3 | 8 |
31 Mar 15 | 0 | -6 | 2 | 6 |
31 Dec 14 | 0 | -4 | 2 | 4 |
30 Sep 14 | 0 | -5 | 2 | 4 |
30 Jun 14 | 0 | -5 | 2 | 3 |
31 Mar 14 | 0 | -5 | 2 | 3 |
31 Dec 13 | 0 | -4 | 2 | 3 |
30 Sep 13 | 0 | -4 | 2 | 3 |
Quality Earnings: VRNA is currently unprofitable.
Growing Profit Margin: VRNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VRNA is unprofitable, and losses have increased over the past 5 years at a rate of 13.9% per year.
Accelerating Growth: Unable to compare VRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRNA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: VRNA has a negative Return on Equity (-21.81%), as it is currently unprofitable.